Mechanistically, MT1G was found to suppress the expression of CPT1B by inhibiting the binding of H3K14m3 to the CPT1B promoter, thereby impeding lipid droplet depletion and facilitating lipid droplet accumulation, ultimately driving ccRCC progression. This evidence concerns the gene MT1G and nonpapillary renal cell carcinoma.